PEPTIDE CORTEXThe library
← The library

GHK-Cu (Copper peptide)

Skin/Hair
Evidence grade
CMixed/unclear regulatory status
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeSkin / Hair
MechanismSignals collagen remodeling and wound repair
EffectsCopper-binding tripeptide (glycyl-histidyl-lysine) found naturally in human plasma; studied mainly in skin and wound-healing models for collagen and tissue-remodelling signals. Not a growth-hormone-axis compound.
DosingNo human dose established.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published2 sourced
Community protocol — not clinically establishedCommunity guide — injectable
RouteSubcutaneous
FrequencyDaily; conservative tier 5 days on / 2 off
StartingConservative 1.0 mg daily, 5 days on / 2 off, 4-week cycle
EscalationStandard 1.0-1.5 mg daily continuous (4-6 weeks); higher end 1.5-2.0 mg daily continuous (6-8 weeks)
Target"1-2 mg per day SubQ for a 4-8 week cycle"
Cycle4-8 weeks depending on tier

"No human RCT has confirmed an optimal injectable schedule." Human data is topical only.

Community protocol — not clinically establishedCommunity guide — topical
RouteTopical (face, scalp)
FrequencyOnce or twice daily
Starting1-2% facial, once or twice daily
EscalationNot stated
TargetTypical formulations 1-3% by weight. Face 1-2%; scalp/hair 1-3% daily.
CycleFacial 8-12 weeks; scalp 12+ weeks ongoing
Batches on file3
100 mgJA-102112 · 2026-0199.45%
80 mgblend · JA-102113 · 2026-01no purity figure
70 mgblend · JA-70756 · 2025-07no purity figure
Read with10
Cautions & interactions

Skin irritation or contact sensitivity possible with topical products. Injected use has not been studied in humans; avoid unverified injectables. It delivers copper: anyone with a copper-metabolism disorder (such as Wilson disease) or a copper allergy should not use it without a clinician.

No established drug-interaction profile in humans. Because it delivers copper, anyone on copper-chelating or copper-restricting treatment (for example for Wilson disease) should not use it without their clinician.

CV 1 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.